Résumé :
|
[BDSP. Notice produite par INIST 8dR0xXlW. Diffusion soumise à autorisation]. Context Pneumococcal conjugate vaccine for infants has recently been found effective against meningitis, bacteremia, pneumonia, and otitis media. Objective To evaluate the projected health and economic impact of pneumococcal conjugate vaccination of healthy US infants and young children. Design Cost-effectiveness analysis based on data from the Northern California Kaiser Permanente randomized trial and other published and unpublished sources. Setting and Patients A hypothetical US birth cohort of 3.8 million infants. Interventions Hypothetical comparisons of routine vaccination of healthy infants, requiring 4 doses of pneumococcal conjugate vaccine (at 2,4,6, and 12-15 months), and catch-up vaccination of children aged 2 to 4.9 years requiring 1 dose, with children receiving no intervention. Main Outcome Measures Cost per life-year saved and cost per episode of meningitis, bacteremia, pneumonia, and otitis media prevented. Results Vaccination of healthy infants would prevent more than 12 000 cases of meningitis and bacteremia, 53 000 cases of pneumonia, 1 million episodes of otitis media, and 116 deaths due to pneumococcal infection. Before accounting for vaccine costs, the vaccination program would save $342 million in medical and $415 million in workloss and other costs from averted pneumococcal disease. (...)
|